"Designing Growth Strategies is in our DNA"
Nonalcoholic steatohepatitis (NASH) is a type of liver inflammation caused due to accumulation of fat in the liver. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) demonstrate very few or no symptoms at the initial stages. Some symptoms such as fatigue, weight loss, general weakness and ache in the upper right part of belly are observed at later stages. The exact cause of NASH is unknown, but some of the common causes include obesity, type 2 diabetes, high cholesterol & triglycerides and metabolic syndrome.
Currently, there are no treatments available of non-alcoholic steatohepatitis (NASH). The first line of treatment is weight loss through a combination of a healthy diet and exercise. In February 2019, Intercept Pharmaceuticals, Inc., announced positive topline results from pivotal phase 3 regenerate study of obeticholic acid in patients with liver fibrosis due to NASH.
Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for non-alcoholic steatohepatitis (NASH) treatment. For instance, Seladelpar, which is being studied by CymaBay Therapeutics, Inc., is currently in phase-2 clinical trials for the study to evaluate seladelpar in subjects with nonalcoholic steatohepatitis (NASH)
To know how our report can help streamline your business, Speak to Analyst
At present around 50% of the pipeline candidates for non-alcoholic steatohepatitis (NASH) treatment are in the phase-1 and phase-2 stage. More than half of the studies are sponsored by industry.
The report on ‘Non-alcoholic Steatohepatitis (NASH) Treatment – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for non-alcoholic steatohepatitis (NASH) treatment. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, and description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for non-alcoholic steatohepatitis (NASH) treatment.
The report on ‘Non-alcoholic Steatohepatitis (NASH) Treatment – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
US +1 833 909 2966 ( Toll Free )